![The Better The AI Gets, The Harder It Is To Ignore](https://cdn.magzter.com/1444374281/1696395526/articles/DPNSsdHik1696408378078/Artificial-Intelligence.jpg)
Insilico Medicine has garnered attention for its innovative utilisation of artificial intelligence (AI) in drug discovery. Could you provide insights into how the industry’s response to AI-based drug discovery has evolved since your inception in 2014?
In the early days, when I presented at conferences on how generative AI technology could be applied to chemistry, there was a lot of scepticism. I had discovered through my research that generative adversarial networks (GANs) combined with deep reinforcement learning (the same AI learning strategy used in AlphaGo) could generate novel molecules that could be used to treat disease. Since that time, AI drug discovery has undergone enormous acceleration, fueled both by advances in AI technology and in massive stores of data. While there are still no AI-designed drugs on the market, there are a number of companies with these drugs in advanced clinical trials, including our own lead drug for idiopathic pulmonary fibrosis, the drug with an AI-discovered target and designed by generative AI now in Phase II trials with patients. Although the pharma industry has moved cautiously, the inherent risks in drug discovery (99 per cent of the drugs fail in the early discovery phase and 90 per cent of the drugs fail in clinical trials) and the validation of AI developed drugs to reach advanced trials, means that pharma companies are more actively pursuing partnerships and developing their own internal AI programmes. We have major partnerships with Exelixis, Sanofi and Fosun Pharma to develop new therapies, for instance.
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Oct 2023 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Oct 2023 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
![Australia invests $1.89B for health and medical research transformation](https://reseuro.magzter.com/100x125/articles/11639/1715375/qrvRAh3Oa1716986540755/AUSTRALIA-INVESTS-189B-FOR-HEALTH-AND-MEDICAL-RESEARCH-TRANSFORMATION.jpg)
Australia invests $1.89B for health and medical research transformation
The government is investing in a once in a generation transformation of health and medical research in Australia.
![NZ suggests new way to prevent rheumatic heart disease progression](https://reseuro.magzter.com/100x125/articles/11639/1715375/5SrlsYiVM1716986443908/NZ-SUGGESTS-NEW-WAY-TO-PREVENT-RHEUMATIC-HEART-DISEASE-PROGRESSION.jpg)
NZ suggests new way to prevent rheumatic heart disease progression
A new way of delivering treatment to prevent rheumatic heart disease progression is significantly less painful than an almost 70-year-old existing treatment, a University of Otago-led study in New Zealand (NZ) has found.
![WHO prequalifies Takeda's dengue vaccine](https://reseuro.magzter.com/100x125/articles/11639/1715375/AmoXG7cCG1716986095712/WHO-PREQUALIFIES-TAKEDAS-DENGUE-VACCINE.jpg)
WHO prequalifies Takeda's dengue vaccine
A new vaccine for dengue has received prequalification from the World Health Organization (WHO).
![GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs](https://reseuro.magzter.com/100x125/articles/11639/1715375/orE_kW9551716985957994/GIBF-INVESTS-10M-IN-ISRAELS-NECTIN-THERAPEUTICS-TO-ADVANCE-ADCS.jpg)
GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs
Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics.
![HOYA Group to distribute AIassisted lesion detection device in US](https://reseuro.magzter.com/100x125/articles/11639/1715375/dgkFOAETp1716985885442/HOYA-GROUP-TO-DISTRIBUTE-AIASSISTED-LESION-DETECTION-DEVICE-IN-US.jpg)
HOYA Group to distribute AIassisted lesion detection device in US
Japan-based HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical, a division of HOYA Group) and MAGENTIQ-EYE, an artificial intelligence (AI)-based medical device company, have announced their intention to form a partnership in the field of AI in gastroenterology and to examine further collaboration and strategic partnerships.
![Saudi Arabia pledges $500M to protect children from polio](https://reseuro.magzter.com/100x125/articles/11639/1715375/pofJAu6991716985823163/SAUDI-ARABIA-PLEDGES-500M-TO-PROTECT-CHILDREN-FROM-POLIO.jpg)
Saudi Arabia pledges $500M to protect children from polio
At the first-ever World Economic Forum (WEF) Special Meeting hosted in Riyadh recently, the Kingdom of Saudi Arabia has pledged $500 million over the next five years to support the work of the Global Polio Eradication Initiative (GPEI).
![Scientists explore use of COVID-19 variant vaccine against other coronaviruses](https://reseuro.magzter.com/100x125/articles/11639/1715375/ZOWoevNXv1716985524639/SCIENTISTS-EXPLORE-USE-OF-COVID19-VARIANT-VACCINE-AGAINST-OTHER-CORONAVIRUSES.jpg)
Scientists explore use of COVID-19 variant vaccine against other coronaviruses
An international consortium of researchers developing a vaccine against troublesome COVID-19 variants will receive additional CEPI funding to investigate whether it could also protect against other deadly coronaviruses.
![How Thai Biotech is Thriving with Innovations](https://reseuro.magzter.com/100x125/articles/11639/1715375/T546PMbxY1716985405176/HOW-THAI-BIOTECH-IS-THRIVING-WITH-INNOVATIONS.jpg)
How Thai Biotech is Thriving with Innovations
Thailand's biotech industry is rapidly evolving, positioning itself as a key player in the ASEAN regions and the global biotechnology landscape. With a strategic focus on research and development, supportive government policies and a burgeoning ecosystem of startups and research institutions, Thailand is emerging as a hotspot for biotech innovation in Southeast Asia.
![Why multi-use real estate is in demand for life sciences companies](https://reseuro.magzter.com/100x125/articles/11639/1715375/qdF2vLJrd1716985245642/WHY-MULTIUSE-REAL-ESTATE-IS-IN-DEMAND-FOR-LIFE-SCIENCES-COMPANIES.jpg)
Why multi-use real estate is in demand for life sciences companies
India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.
!["The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"](https://reseuro.magzter.com/100x125/articles/11639/1715375/4srGs8m_z1716984891829/THE-DIALOGUE-SURROUNDING-PHARMACEUTICAL-GOWNING-IS-EXPERIENCING-SIGNIFICANT-TRANSFORMATION-IN-2024-BEYOND.jpg)
"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"
Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.